Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in Prostate Cancer: Patient Selection, Treatment Workflow, and Emerging Directions.

Created on 17 Nov 2026

Authors

Dilara Denizmen Zorba, Yasemin Sanli

Published in

Magnetic resonance imaging clinics of North America. Volume 35. Issue 1. Pages 177-188. Epub Oct 23, 2026.

Abstract

Prostate-specific membrane antigen (PSMA)-targeted theranostics have become an important component of advanced prostate cancer management by integrating molecular imaging with radioligand therapy. This review summarizes the biologic rationale for PSMA targeting, the role of PSMA PET in patient selection, and the clinical evidence supporting PSMA-directed radioligand therapy. Practical aspects of treatment administration, toxicity monitoring, response assessment, and sequencing are discussed, together with emerging strategies involving novel ligands, alpha emitters, dosimetry, and combination approaches.

PMID:
43039498
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement